HCW Biologics closes exclusive worldwide license for HCW11-006; receives $7M upfront fee

HCW Biologics Inc.

Total upfront fee of $7.0M: $3.5M cash plus $3.5M transferable equity interest in licensee Trimmune.
HCW eligible for development milestones, double-digit royalties on future sales, and proceeds from future transactions.
HCW has free option to recapture Americas rights after Phase 1 in China; Phase 1 expected H1 2027.
Trimmune granted option to license HCW9302 for China; additional payments due if option exercised.

item 1.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.